@FiercePharma: Michigan governor urges Perrigo shareholders to reject Mylan's offer. Story | Follow @FiercePharma
@CarlyHFierce: Good news for Allergan: Men want to treat wrinkles. Bad? They're clueless about products. Story | Follow @CarlyHFierce
> Merck KGaA cleared a major antitrust hurdle to its planned $17 billion buyout of Sigma-Aldrich ($SIAL) as it agreed to sell some assets to Honeywell ($HON). Report
> German cost-effectiveness gatekeepers decided that Bristol-Myers Squibb's ($BMY) immuno-oncology treatment Opdivo offers an "added benefit" over previous treatments, particularly in men. Report
> Healthcare system executives say ongoing shortages and drug-price spikes are among their top worries, according to a new Premier survey. Release
> The U.S. government plans to offer new training to healthcare providers who prescribe narcotic painkillers and direct federal agencies to make the overdose remedy naloxone more readily available to people covered by their health plans. Report
> Microsoft ($MSFT) nominated Johnson & Johnson ($JNJ) exec Sandra Peterson to serve on its board. Report
> Allergan ($ACT) expanded its portfolio of dry-eye remedies with the launch of the over-the-counter Refresh Optive Gel Drops. Release
> LEO Pharma won FDA approval for Enstilar, its topical foam treatment for psoriasis vulgaris in patients 18 and older. Report
Medical Device News
@FierceMedDev: Check out this year's Fierce 15: The new strategic med tech mania sets the stage for 2015's Fierce 15. Feature | Follow @FierceMedDev
@VarunSaxena2: Fierce 15 co. Shockwave Medical aims to deploy energy-delivering balloons in the peripheral and coronary arteries. More | Follow @VarunSaxena2
@EmilyWFierce: Discovery of the day: Former "Daria" director illustrated and directed $PFE's Zoloft sad blob commercials. More | Follow @EmilyWFierce
> American Cancer Society guidelines updated to recommend fewer mammograms. Item
> Rheonix bags $28M for molecular testing platforms. Report
Biotech News
@FierceBiotech: Novartis inks a string of deals to widen its immuno-oncology arsenal. Article | Follow @FierceBiotech
@JohnCFierce: $AZN's lesinurad is a mess. Safety issues, efficacy ???. Another test for the 'new' FDA. I suspect it gets approved. News | Follow @JohnCFierce
@DamianFierce: $BIIB things I forgot to mention:U.S. royalties on $RHBBY's ocrelizumab are 13.5% to 24%--STX-100 not affected by fibrosis cuts. | Follow @DamianFierce
> Big Pharma backs $100M dementia R&D fund. Item
> Synta gets decimated after its lead cancer drug comes up short in Phase III. Story
Biotech Research News
> King's College team IDs a gene target for Parkinson's. Report
> Georgetown researchers flag success of pilot Parkinson's drug study. More
> Gene therapy for brain protein boosts memory in aged mice. Article
> RIKEN mouse study sheds new light on depression. Item
> MicroRNA controls tissue-specific PTEN expression in brain cancer. Story
Vaccines News
> Sanofi, Gates Foundation and IDRI team up to improve vaccine development process. News
> Cancer vaccines field sees new player emerge with Gritstone's $102M Series A. More
> Inovio's MERS vaccine could hit PhI before year's end. Story
> CSL to buy back $723M of its shares. Item
> Genocea puts pneumococcal vaccine on back burner following PhII failure. Article
Pharma Marketing News
> Good news for Allergan: Men want to treat wrinkles. Bad? They're clueless about products. Story
> PCSK9 drugmakers go Big Data to ID more eligible patients. Report
> Relypsa, Sanofi marketing teams revved up and waiting for FDA nod on patiromer. Article
> AstraZeneca touts new Russian plant as boon for emerging markets sales. Item
> Angling for more reach with providers, Merck melds Univadis unit with Physicians Interactive. More
And Finally... Novartis' ($NVS) new affordable-drugs scheme for emerging markets launched in Kenya. Release